Novavax (NASDAQ: NVAX) reported Q4 EPS of ($2.28), $1.09 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $357 million versus the consensus estimate of $383.14 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.